AFL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aflac Inc is not a strong buy for a beginner investor with a long-term strategy at this time. While the technical indicators are generally bullish and the SwingMax signal suggests a potential short-term opportunity, the financial performance has been weak, and insider selling raises concerns. Additionally, analysts' ratings and price targets are mixed, with no strong upward momentum. It would be prudent to monitor the stock for better entry points or improved financial performance.
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone at 68.156, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 109.886 and 111.013, with support at 106.238 and 105.111.
Hedge funds are significantly increasing their positions, with a 695012.50% rise in buying over the last quarter.
Aflac's strategic reinsurance agreements with Japan Post Insurance could strengthen its market position and financial stability.
SwingMax signal on 2026-03-31 suggests potential for short-term gains.
Insiders are selling heavily, with a 1299.53% increase in selling activity over the last month.
Financial performance in Q4 2025 was weak, with revenue down 9.94% YoY, net income down 27.50%, and EPS down 22.81%.
Analysts' ratings are mixed, with no strong consensus for a buy.
In Q4 2025, Aflac's revenue dropped to $4.87 billion (-9.94% YoY), net income fell to $1.38 billion (-27.50% YoY), and EPS declined to 2.64 (-22.81% YoY). This indicates a challenging financial period with declining profitability.
Analysts' ratings are mixed. Keefe Bruyette re-initiated coverage with a Market Perform rating and a $113 price target. Wells Fargo raised its price target to $118 but maintained an Equal Weight rating. TD Cowen and Barclays lowered their price targets to $100 and $101, respectively, citing sector headwinds. BofA maintained a Buy rating with a reduced price target of $120, while JPMorgan raised its target to $105 with a Neutral rating.
